Q2-osavuosiraportti
90 päivää sitten‧40 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
11 100
Myynti
Määrä
6 661
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 414 | NON | SSWM | ||
| 2 167 | NON | NON | ||
| 980 | NON | NON | ||
| 304 | DDB | NON | ||
| 2 496 | DDB | NON |
Ylin
6,62VWAP
Alin
6,22VaihtoMäärä
0,6 92 810
VWAP
Ylin
6,62Alin
6,22VaihtoMäärä
0,6 92 810
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 13 769 | 1 023 | +12 746 | 1 023 |
| Nordea Bank Abp | 6 907 | 0 | +6 907 | 0 |
| Skandinaviska Enskilda Banken AB | 1 510 | 0 | +1 510 | 0 |
| SSW Market Making GmbH | 490 | 490 | 0 | 0 |
| Svenska Handelsbanken AB | 0 | 500 | −500 | 0 |
| Avanza Bank AB | 7 517 | 15 312 | −7 795 | 2 415 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 62 617 | 75 485 | −12 868 | 55 255 |
| Avanza Bank AB | 7 517 | 15 312 | −7 795 | 2 415 |
| Svenska Handelsbanken AB | 0 | 500 | −500 | 0 |
| SSW Market Making GmbH | 490 | 490 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 1 510 | 0 | +1 510 | 0 |
| Nordea Bank Abp | 6 907 | 0 | +6 907 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 28.5. | |
| Merkintäoikeusanti | 30.4. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2025 Ylimääräinen yhtiökokous | 23.4. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
10 t sitten10 t sittenTämä julkaisu on poistettu.
·11 t sittenIt will probably look like it has in previous years. Nothing to pay attention to.·9 t sittenI'm very well-versed. Been in it from the start 😎 scroll on now amateur
13 t sitten13 t sittenSå kom nyheden: urasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT® Site given green light by European Medicines Agency (EMA) and is now open for patient enrollment – first patient dosing expected Q4 2025 Both arms of Curasight’s theranostic approach investigating better treatment (uTREAT®) and diagnosis (uTRACE®) of certain cancers are now in clinical development Copenhagen, 26 November 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced its phase 1 trial investigating uTREAT® in aggressive brain cancer is now open for patient enrollment. Regulatory approval from the Health Authority and ethical committee approval has been obtained, and all practical and logistical preparations at the trial site have been completed. Dosing the first patient is expected in the coming weeks. The phase 1 trial is part of Curasight’s theranostic strategy developing more gentle and targeted diagnosis and treatment of certain types of cancer. “It is a very exciting stage in the development of uTREAT, that we are now ready to enroll patients and progress the development of uTREAT as a potential more targeted therapeutic solution for patients with aggressive brain cancer. There is a high unmet medical need for new treatments for brain cancer, and we look forward to enrolling the first patient very soon” said Curasight’s CEO Ulrich Krasilnikoff. About the Phase 1 trial with uTREAT in brain cancer The trial aims to investigate Curasight’s uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from clinical studies with the ligand forming the backbone of uTRACE®, demonstrating that almost all GBM patients (94%), express uPAR on the tumour. About the uPAR theranostic platform Curasight’s uPAR theranostic platform combines two key technologies - uTRACE and uTREAT both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight’s ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers. About high grade glioma Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50% of the patients die within 14 months and after five years from diagnosis only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT could potentially replace or reduce the use of external beam radiation and thereby lower side effects to the healthy brain due to more specific tumor tissue targeting.
·1 päivä sitten · MuokattuI just wanted to give a short little update to everyone. Nov. 27) the Q3 report is coming → cash until mid-2026 + update on FPD (first patient dosed in uTREAT®) which is still planned before the end of the year All 9 European sites in prostate cancer phase 2 are already recruiting at full speed. Curium (the world's largest nuclear medicine player) just put a new Lu-177 supply agreement on the table + invested heavily in the spring → they believe so much in this that they are both financing and will produce globally. The patent for uTRACE was extended and strengthened in October The market for precision diagnostics + therapy in prostate cancer alone is 10+ billion USD annually – and CURAS has a platform that potentially beats PSMA in sensitivity And yet… the stock is still down at a market cap of around 250–300 million DKK. This is the classic biotech setup just before it explodes: Thin buy side → a single piece of news (FPD or positive earnings comment) → volume explodes → 8–12 kr in a few days → everyone runs after and shouts “why didn't I get in at the 5s ??? Have a good day out there everyone.
·1 päivä sittenYes, very much the situation boiled down to its essence. And if it wasn't for the chaos in the spring, it would undoubtedly already be double. I hope for the company that they can deliver what is promised; FPD could suitably arrive before November ends and not be squeezed in at Christmas time with a delay on prelm.data. Because they have something to fix, investor confidence has taken a hit in the spring, and now would be perfect timing to wipe the slate clean. Because the essence of the case right now. the central aspects, certainly make it one of the most exciting I have ever invested in. The potential is so enormous, and one is really not many relatively probable announcements away from the share price skyrocketing. It can also go wrong, but I just think that if you weigh potential upside against the chance of success, it's a no brainer. You go into Curasight, everything else makes no sense. You can certainly lose everything, but if you had the chance to buy 10,000 lottery tickets for a fraction of the tickets' real price, wouldn't you allocate the money to do it? That's the feeling I have with Curasight at this stage. Disclaimer, I own a significant amount of shares in Cura and am naturally biased. I believe in it.- ·1 päivä sittenStill thin bid side, no significant turnover. It would be nice with the first patient dose news soon, so one can sort of turn the page there. Now one sincerely hopes for them that they can deliver what they promise people and regain credibility and trust in the case. The financial report will hardly be of much relevance, or is there something I'm overlooking?·1 päivä sittenHow long have you been following along? Just need to understand if you are sarcastic or if it's a real question.·1 päivä sittenHi Mads, as you can see from the share price, it has taken a significant dip. It fell due to a large capital raise, where a rights issue was carried out at a very, very low subscription price. It was not fun to be an existing shareholder at that time. And many will probably not go into it again now (the trust just isn't there..). In addition, low participation to support a claim that the market reacted very, very negatively to it. They have certainly lost some people along the way who wouldn't touch it with a ten-foot pole. Remember, there are people who not too long ago bought in at a price that is x5-8 times today's price.. That's still massive. If you have sold a share with such a large loss, for example.., then there is some trust that needs to be restored from the company's side before this person can be brought back on board. But. Now the share price has been down and turned around. and I dare say that if it weren't for this "open wound" from the time before summer 2025, the price would already be double. Now the company has something to prove. I sincerely hope for them that they deliver on what they so clearly announce. I mean.. He stood at the investor day the other day and said... "uhh boo.. I can't say.. uhh boo, it could be days, it could be weeks.. uhh boo.. but soon".. Q4 has been announced and it would be appropriate to be ready with it soon - not just squeezed in between Christmas presents and New Year's hat in an attempt to keep a promise. First patient dose: should come soon, if the share price is not to lose momentum again. prelm. data should come relatively quickly after, but again it will be exciting to see if they can deliver as they say. Others may correct me if I'm wrong, but after first patient dose, it should be possible after not very many days to come with preliminary data. So it's no use having first patient dose on December 15 and still not having any data announced on Christmas Eve. Then I think again that the company is failing in terms of creating trust-inspiring communication with its investors.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
90 päivää sitten‧40 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 10 t sitten10 t sittenTämä julkaisu on poistettu.·11 t sittenIt will probably look like it has in previous years. Nothing to pay attention to.·9 t sittenI'm very well-versed. Been in it from the start 😎 scroll on now amateur
- 13 t sitten13 t sittenSå kom nyheden: urasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT® Site given green light by European Medicines Agency (EMA) and is now open for patient enrollment – first patient dosing expected Q4 2025 Both arms of Curasight’s theranostic approach investigating better treatment (uTREAT®) and diagnosis (uTRACE®) of certain cancers are now in clinical development Copenhagen, 26 November 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced its phase 1 trial investigating uTREAT® in aggressive brain cancer is now open for patient enrollment. Regulatory approval from the Health Authority and ethical committee approval has been obtained, and all practical and logistical preparations at the trial site have been completed. Dosing the first patient is expected in the coming weeks. The phase 1 trial is part of Curasight’s theranostic strategy developing more gentle and targeted diagnosis and treatment of certain types of cancer. “It is a very exciting stage in the development of uTREAT, that we are now ready to enroll patients and progress the development of uTREAT as a potential more targeted therapeutic solution for patients with aggressive brain cancer. There is a high unmet medical need for new treatments for brain cancer, and we look forward to enrolling the first patient very soon” said Curasight’s CEO Ulrich Krasilnikoff. About the Phase 1 trial with uTREAT in brain cancer The trial aims to investigate Curasight’s uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from clinical studies with the ligand forming the backbone of uTRACE®, demonstrating that almost all GBM patients (94%), express uPAR on the tumour. About the uPAR theranostic platform Curasight’s uPAR theranostic platform combines two key technologies - uTRACE and uTREAT both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight’s ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers. About high grade glioma Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50% of the patients die within 14 months and after five years from diagnosis only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT could potentially replace or reduce the use of external beam radiation and thereby lower side effects to the healthy brain due to more specific tumor tissue targeting.
- ·1 päivä sitten · MuokattuI just wanted to give a short little update to everyone. Nov. 27) the Q3 report is coming → cash until mid-2026 + update on FPD (first patient dosed in uTREAT®) which is still planned before the end of the year All 9 European sites in prostate cancer phase 2 are already recruiting at full speed. Curium (the world's largest nuclear medicine player) just put a new Lu-177 supply agreement on the table + invested heavily in the spring → they believe so much in this that they are both financing and will produce globally. The patent for uTRACE was extended and strengthened in October The market for precision diagnostics + therapy in prostate cancer alone is 10+ billion USD annually – and CURAS has a platform that potentially beats PSMA in sensitivity And yet… the stock is still down at a market cap of around 250–300 million DKK. This is the classic biotech setup just before it explodes: Thin buy side → a single piece of news (FPD or positive earnings comment) → volume explodes → 8–12 kr in a few days → everyone runs after and shouts “why didn't I get in at the 5s ??? Have a good day out there everyone.·1 päivä sittenYes, very much the situation boiled down to its essence. And if it wasn't for the chaos in the spring, it would undoubtedly already be double. I hope for the company that they can deliver what is promised; FPD could suitably arrive before November ends and not be squeezed in at Christmas time with a delay on prelm.data. Because they have something to fix, investor confidence has taken a hit in the spring, and now would be perfect timing to wipe the slate clean. Because the essence of the case right now. the central aspects, certainly make it one of the most exciting I have ever invested in. The potential is so enormous, and one is really not many relatively probable announcements away from the share price skyrocketing. It can also go wrong, but I just think that if you weigh potential upside against the chance of success, it's a no brainer. You go into Curasight, everything else makes no sense. You can certainly lose everything, but if you had the chance to buy 10,000 lottery tickets for a fraction of the tickets' real price, wouldn't you allocate the money to do it? That's the feeling I have with Curasight at this stage. Disclaimer, I own a significant amount of shares in Cura and am naturally biased. I believe in it.
- ·1 päivä sittenStill thin bid side, no significant turnover. It would be nice with the first patient dose news soon, so one can sort of turn the page there. Now one sincerely hopes for them that they can deliver what they promise people and regain credibility and trust in the case. The financial report will hardly be of much relevance, or is there something I'm overlooking?·1 päivä sittenHow long have you been following along? Just need to understand if you are sarcastic or if it's a real question.·1 päivä sittenHi Mads, as you can see from the share price, it has taken a significant dip. It fell due to a large capital raise, where a rights issue was carried out at a very, very low subscription price. It was not fun to be an existing shareholder at that time. And many will probably not go into it again now (the trust just isn't there..). In addition, low participation to support a claim that the market reacted very, very negatively to it. They have certainly lost some people along the way who wouldn't touch it with a ten-foot pole. Remember, there are people who not too long ago bought in at a price that is x5-8 times today's price.. That's still massive. If you have sold a share with such a large loss, for example.., then there is some trust that needs to be restored from the company's side before this person can be brought back on board. But. Now the share price has been down and turned around. and I dare say that if it weren't for this "open wound" from the time before summer 2025, the price would already be double. Now the company has something to prove. I sincerely hope for them that they deliver on what they so clearly announce. I mean.. He stood at the investor day the other day and said... "uhh boo.. I can't say.. uhh boo, it could be days, it could be weeks.. uhh boo.. but soon".. Q4 has been announced and it would be appropriate to be ready with it soon - not just squeezed in between Christmas presents and New Year's hat in an attempt to keep a promise. First patient dose: should come soon, if the share price is not to lose momentum again. prelm. data should come relatively quickly after, but again it will be exciting to see if they can deliver as they say. Others may correct me if I'm wrong, but after first patient dose, it should be possible after not very many days to come with preliminary data. So it's no use having first patient dose on December 15 and still not having any data announced on Christmas Eve. Then I think again that the company is failing in terms of creating trust-inspiring communication with its investors.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
11 100
Myynti
Määrä
6 661
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 414 | NON | SSWM | ||
| 2 167 | NON | NON | ||
| 980 | NON | NON | ||
| 304 | DDB | NON | ||
| 2 496 | DDB | NON |
Ylin
6,62VWAP
Alin
6,22VaihtoMäärä
0,6 92 810
VWAP
Ylin
6,62Alin
6,22VaihtoMäärä
0,6 92 810
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 13 769 | 1 023 | +12 746 | 1 023 |
| Nordea Bank Abp | 6 907 | 0 | +6 907 | 0 |
| Skandinaviska Enskilda Banken AB | 1 510 | 0 | +1 510 | 0 |
| SSW Market Making GmbH | 490 | 490 | 0 | 0 |
| Svenska Handelsbanken AB | 0 | 500 | −500 | 0 |
| Avanza Bank AB | 7 517 | 15 312 | −7 795 | 2 415 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 62 617 | 75 485 | −12 868 | 55 255 |
| Avanza Bank AB | 7 517 | 15 312 | −7 795 | 2 415 |
| Svenska Handelsbanken AB | 0 | 500 | −500 | 0 |
| SSW Market Making GmbH | 490 | 490 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 1 510 | 0 | +1 510 | 0 |
| Nordea Bank Abp | 6 907 | 0 | +6 907 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 28.5. | |
| Merkintäoikeusanti | 30.4. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2025 Ylimääräinen yhtiökokous | 23.4. |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
90 päivää sitten‧40 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 28.5. | |
| Merkintäoikeusanti | 30.4. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2025 Ylimääräinen yhtiökokous | 23.4. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 10 t sitten10 t sittenTämä julkaisu on poistettu.·11 t sittenIt will probably look like it has in previous years. Nothing to pay attention to.·9 t sittenI'm very well-versed. Been in it from the start 😎 scroll on now amateur
- 13 t sitten13 t sittenSå kom nyheden: urasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT® Site given green light by European Medicines Agency (EMA) and is now open for patient enrollment – first patient dosing expected Q4 2025 Both arms of Curasight’s theranostic approach investigating better treatment (uTREAT®) and diagnosis (uTRACE®) of certain cancers are now in clinical development Copenhagen, 26 November 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced its phase 1 trial investigating uTREAT® in aggressive brain cancer is now open for patient enrollment. Regulatory approval from the Health Authority and ethical committee approval has been obtained, and all practical and logistical preparations at the trial site have been completed. Dosing the first patient is expected in the coming weeks. The phase 1 trial is part of Curasight’s theranostic strategy developing more gentle and targeted diagnosis and treatment of certain types of cancer. “It is a very exciting stage in the development of uTREAT, that we are now ready to enroll patients and progress the development of uTREAT as a potential more targeted therapeutic solution for patients with aggressive brain cancer. There is a high unmet medical need for new treatments for brain cancer, and we look forward to enrolling the first patient very soon” said Curasight’s CEO Ulrich Krasilnikoff. About the Phase 1 trial with uTREAT in brain cancer The trial aims to investigate Curasight’s uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from clinical studies with the ligand forming the backbone of uTRACE®, demonstrating that almost all GBM patients (94%), express uPAR on the tumour. About the uPAR theranostic platform Curasight’s uPAR theranostic platform combines two key technologies - uTRACE and uTREAT both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight’s ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers. About high grade glioma Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50% of the patients die within 14 months and after five years from diagnosis only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT could potentially replace or reduce the use of external beam radiation and thereby lower side effects to the healthy brain due to more specific tumor tissue targeting.
- ·1 päivä sitten · MuokattuI just wanted to give a short little update to everyone. Nov. 27) the Q3 report is coming → cash until mid-2026 + update on FPD (first patient dosed in uTREAT®) which is still planned before the end of the year All 9 European sites in prostate cancer phase 2 are already recruiting at full speed. Curium (the world's largest nuclear medicine player) just put a new Lu-177 supply agreement on the table + invested heavily in the spring → they believe so much in this that they are both financing and will produce globally. The patent for uTRACE was extended and strengthened in October The market for precision diagnostics + therapy in prostate cancer alone is 10+ billion USD annually – and CURAS has a platform that potentially beats PSMA in sensitivity And yet… the stock is still down at a market cap of around 250–300 million DKK. This is the classic biotech setup just before it explodes: Thin buy side → a single piece of news (FPD or positive earnings comment) → volume explodes → 8–12 kr in a few days → everyone runs after and shouts “why didn't I get in at the 5s ??? Have a good day out there everyone.·1 päivä sittenYes, very much the situation boiled down to its essence. And if it wasn't for the chaos in the spring, it would undoubtedly already be double. I hope for the company that they can deliver what is promised; FPD could suitably arrive before November ends and not be squeezed in at Christmas time with a delay on prelm.data. Because they have something to fix, investor confidence has taken a hit in the spring, and now would be perfect timing to wipe the slate clean. Because the essence of the case right now. the central aspects, certainly make it one of the most exciting I have ever invested in. The potential is so enormous, and one is really not many relatively probable announcements away from the share price skyrocketing. It can also go wrong, but I just think that if you weigh potential upside against the chance of success, it's a no brainer. You go into Curasight, everything else makes no sense. You can certainly lose everything, but if you had the chance to buy 10,000 lottery tickets for a fraction of the tickets' real price, wouldn't you allocate the money to do it? That's the feeling I have with Curasight at this stage. Disclaimer, I own a significant amount of shares in Cura and am naturally biased. I believe in it.
- ·1 päivä sittenStill thin bid side, no significant turnover. It would be nice with the first patient dose news soon, so one can sort of turn the page there. Now one sincerely hopes for them that they can deliver what they promise people and regain credibility and trust in the case. The financial report will hardly be of much relevance, or is there something I'm overlooking?·1 päivä sittenHow long have you been following along? Just need to understand if you are sarcastic or if it's a real question.·1 päivä sittenHi Mads, as you can see from the share price, it has taken a significant dip. It fell due to a large capital raise, where a rights issue was carried out at a very, very low subscription price. It was not fun to be an existing shareholder at that time. And many will probably not go into it again now (the trust just isn't there..). In addition, low participation to support a claim that the market reacted very, very negatively to it. They have certainly lost some people along the way who wouldn't touch it with a ten-foot pole. Remember, there are people who not too long ago bought in at a price that is x5-8 times today's price.. That's still massive. If you have sold a share with such a large loss, for example.., then there is some trust that needs to be restored from the company's side before this person can be brought back on board. But. Now the share price has been down and turned around. and I dare say that if it weren't for this "open wound" from the time before summer 2025, the price would already be double. Now the company has something to prove. I sincerely hope for them that they deliver on what they so clearly announce. I mean.. He stood at the investor day the other day and said... "uhh boo.. I can't say.. uhh boo, it could be days, it could be weeks.. uhh boo.. but soon".. Q4 has been announced and it would be appropriate to be ready with it soon - not just squeezed in between Christmas presents and New Year's hat in an attempt to keep a promise. First patient dose: should come soon, if the share price is not to lose momentum again. prelm. data should come relatively quickly after, but again it will be exciting to see if they can deliver as they say. Others may correct me if I'm wrong, but after first patient dose, it should be possible after not very many days to come with preliminary data. So it's no use having first patient dose on December 15 and still not having any data announced on Christmas Eve. Then I think again that the company is failing in terms of creating trust-inspiring communication with its investors.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
11 100
Myynti
Määrä
6 661
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 414 | NON | SSWM | ||
| 2 167 | NON | NON | ||
| 980 | NON | NON | ||
| 304 | DDB | NON | ||
| 2 496 | DDB | NON |
Ylin
6,62VWAP
Alin
6,22VaihtoMäärä
0,6 92 810
VWAP
Ylin
6,62Alin
6,22VaihtoMäärä
0,6 92 810
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 13 769 | 1 023 | +12 746 | 1 023 |
| Nordea Bank Abp | 6 907 | 0 | +6 907 | 0 |
| Skandinaviska Enskilda Banken AB | 1 510 | 0 | +1 510 | 0 |
| SSW Market Making GmbH | 490 | 490 | 0 | 0 |
| Svenska Handelsbanken AB | 0 | 500 | −500 | 0 |
| Avanza Bank AB | 7 517 | 15 312 | −7 795 | 2 415 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 62 617 | 75 485 | −12 868 | 55 255 |
| Avanza Bank AB | 7 517 | 15 312 | −7 795 | 2 415 |
| Svenska Handelsbanken AB | 0 | 500 | −500 | 0 |
| SSW Market Making GmbH | 490 | 490 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 1 510 | 0 | +1 510 | 0 |
| Nordea Bank Abp | 6 907 | 0 | +6 907 | 0 |